Authors
Latest:
Pricing for Rare Disease and Curative Therapies: What’s Fair?There has been a considerable amount of attention given to the rising costs of pharmaceutical and biotechnology therapies in the US. In early 2020, Charles River Associates conducted this research to determine what "fair" prices would be for these therapies.
Latest:
Pharma’s Choice After COVID: Hero or VillainFollowing the COVID-19 pandemic, will drug companies be able to tame subdued anger against the industry by creating meaningful drug innovations?
Latest:
Managing the COVID-19 Drug Safety ResponseCurrent safety reporting systems cannot meet the demands of a COVID-19 response. Find out how digital transformation enables rapid understanding & management of drug safety.
Latest:
Cancer Patients Can Not Afford To Put Their Struggle on HoldWith widescale collaboration among companies, academia, and the science community to solve COVID-19, we can hope that this crisis has acted as a catalyst to increase positive perception for the biopharma industry.
Latest:
Medical Affairs and Medical Science Liaison (MSL) Board Certification: A Comprehensive ReviewWith the growth of the medical science liaison (MSL) role in mind, this article provides a comprehensive review of the board certification programs that are currently available to MSLs and other medical affairs professionals.
Latest:
Medical Affairs and Medical Science Liaison (MSL) Board Certification: A Comprehensive ReviewWith the growth of the medical science liaison (MSL) role in mind, this article provides a comprehensive review of the board certification programs that are currently available to MSLs and other medical affairs professionals.
Latest:
Medical Affairs and Medical Science Liaison (MSL) Board Certification: A Comprehensive ReviewWith the growth of the medical science liaison (MSL) role in mind, this article provides a comprehensive review of the board certification programs that are currently available to MSLs and other medical affairs professionals.
Latest:
How Pharma Can Help Address Physician Burnout–Amplifying the Voice of the PhysicianPrescribers cite ways to alleviate systemic threats to their ability to serve.
Latest:
Future-Proofing CRM Investments in Life Sciences: Observations from Dreamforce 2024The future is bright with AI-powered innovations, but migration presents significant risks, including data loss, increased costs, and disruption to business operations.
Latest:
The Pharma Supply Chain: Responding to COVID-19Taking stock of evolving practices in protecting the supply chain amid the pandemic, including partnering and planning for what’s next.
Latest:
Outlining Current and Future Trends in Medical InformationWith the role of Medical Information in pharma companies changing in recent years, this article outlines some current and future trends including globalization and the use of data to drive change.
Latest:
A Rare-Disease Must? Building Long-Term RelationshipsThe importance of life sciences companies focused on rare diseases to take early steps to bridge connections with patients, caregivers, and healthcare providers.
Latest:
COVID-19 Action Plan for Ethics and Compliance TeamsCompliance officers from the life sciences industry joined together recently to discuss how the COVID-19 pandemic has changed the ways we live and work, and how those changes have impacted the life sciences industry as a whole and will continue to do so in the future.
Latest:
New Standards for First-to-Launch PlayersWhile COVID-19 has shifted some of the rules, research reveals that practice changes were already afoot for market newcomers.
Latest:
How Can Pharma Companies Join the Digital Therapeutics Revolution?More and more companies are joining forces with software developers to create innovative products. But many are learning the hard way that making next-generation digital therapeutics isn’t as easy as signing a partnership agreement.
Latest:
New Standards for First-to-Launch PlayersWhile COVID-19 has shifted some of the rules, research reveals that practice changes were already afoot for market newcomers.
Latest:
E-Labeling: Change is UnderwayPriyanka Chaudhary and Vikram Shetty outline the current challenges and opportunities presented by e-labeling around the world.
Latest:
How Will COVID-19 Affect the Financing of Healthcare Provision Across the US?As providers and payers exert ever greater pressure on the pharma industry, will they force manufacturers to offer significant pricing concessions and will this become the new normal for the US healthcare system? Brett Gardiner reports.
Latest:
Leverage Compliance Activities to Drive Data-Driven SuccessXavier Duburcq describes how pharma leaders can convert compliance from a cost center to a critical success factor.
Latest:
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia GravisApproval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
Latest:
Big Events Go Virtual: A Look Inside One TransformationThe transition from in-person was challenging, but meetings like DIA’s global event could explore formal hybrid models in the future.
Latest:
Preparing to Share Regulatory Data: 5 Practical TipsDuncan van Rijsbergen highlights key considerations for life sciences companies tackling data quality issues.
Latest:
Culture and Compliance: Building a Culture of Business EthicsAmid the limitations of traditional compliance programs that emphasize control measures, here are steps biopharma companies can implement in their own cultures to ensure they’re behaving and performing with integrity.
Latest:
Culture and Compliance: Building a Culture of Business EthicsAmid the limitations of traditional compliance programs that emphasize control measures, here are steps biopharma companies can implement in their own cultures to ensure they’re behaving and performing with integrity.
Latest:
Enterprise Leadership: Is Compliance Ripe for Disruption?Case study illustrates how compliance teams, in today’s climate, can foster innovation across an organization to help achieve corporate goals.
Latest:
Enterprise Leadership: Is Compliance Ripe for Disruption?Case study illustrates how compliance teams, in today’s climate, can foster innovation across an organization to help achieve corporate goals.
Latest:
Turning Safety and Regulatory to Business Driver with Natural Language ProcessingTo save time spent on manual reporting, pharmaceutical companies are turning to Natural Language Processing (NLP) which holds the combined potential for automating processes and enabling a deeper understanding of previously untapped data.
Latest:
Turning Safety and Regulatory to Business Driver with Natural Language ProcessingTo save time spent on manual reporting, pharmaceutical companies are turning to Natural Language Processing (NLP) which holds the combined potential for automating processes and enabling a deeper understanding of previously untapped data.
Latest:
How Oncologists are Coping with COVID-19Report highlights how oncology practices are becoming more virtual-oriented in light of the global pandemic.
Latest:
Strategic Realignment for a Better FutureIn adjusting to the long-term side-effects of the coronavirus pandemic, pharma companies will need to focus on change in three areas. Ben van der Schaaf and Aurelien Guichard report.
